Harrow (NASDAQ:HROW) Shares Up 7.7% – Time to Buy?

Shares of Harrow, Inc. (NASDAQ:HROW) rose 7.7% during mid-day trading on Thursday . The stock traded as high as $36.24 and last traded at $36.15. 295,975 shares traded hands during mid-day trading, a decline of 41% from the average session volume of 497,813 shares. The stock had previously closed at $33.55.

Analysts Set New Price Targets

Several analysts recently commented on the company. Craig Hallum raised their price objective on Harrow from $45.00 to $65.00 and gave the stock a “buy” rating in a research note on Friday, October 4th. B. Riley dropped their price target on Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a research report on Wednesday, December 4th. Finally, Lake Street Capital boosted their price objective on Harrow from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Friday, October 4th.

Harrow Stock Down 0.6 %

The firm has a market capitalization of $1.29 billion, a P/E ratio of -38.66 and a beta of 0.69. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. The firm’s 50-day moving average is $40.54 and its 200 day moving average is $37.66.

Institutional Investors Weigh In On Harrow

Institutional investors have recently bought and sold shares of the company. Quest Partners LLC bought a new stake in Harrow during the third quarter worth about $29,000. nVerses Capital LLC acquired a new position in shares of Harrow during the 2nd quarter worth about $33,000. Allspring Global Investments Holdings LLC lifted its stake in Harrow by 2,730.7% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company’s stock valued at $44,000 after purchasing an additional 2,048 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Harrow by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock worth $57,000 after purchasing an additional 227 shares during the period. Finally, Hills Bank & Trust Co acquired a new position in Harrow during the third quarter worth approximately $107,000. Institutional investors own 72.76% of the company’s stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.